ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,654,154 | -16.3% | 5,213,731 | -3.8% | 0.01% | -14.3% |
| Q2 2023 | $129,816,616 | +23.5% | 5,420,318 | -3.0% | 0.01% | +16.7% |
| Q1 2023 | $105,144,724 | -57.3% | 5,586,861 | -63.9% | 0.01% | -14.3% |
| Q4 2022 | $246,452,362 | +122.2% | 15,480,676 | +128.4% | 0.01% | 0.0% |
| Q3 2022 | $110,902,000 | +19.4% | 6,778,871 | +2.8% | 0.01% | +16.7% |
| Q2 2022 | $92,909,000 | -24.1% | 6,593,950 | +30.4% | 0.01% | 0.0% |
| Q1 2022 | $122,485,000 | +8.9% | 5,057,194 | +4.9% | 0.01% | +20.0% |
| Q4 2021 | $112,498,000 | +18.2% | 4,819,953 | -15.9% | 0.01% | 0.0% |
| Q3 2021 | $95,147,000 | -1.8% | 5,728,323 | +44.3% | 0.01% | 0.0% |
| Q2 2021 | $96,843,000 | +17.0% | 3,970,611 | +23.7% | 0.01% | 0.0% |
| Q1 2021 | $82,783,000 | -40.7% | 3,208,638 | +22.9% | 0.01% | -44.4% |
| Q4 2020 | $139,521,000 | +25.2% | 2,609,826 | -3.4% | 0.01% | +12.5% |
| Q3 2020 | $111,482,000 | -10.4% | 2,702,584 | +5.3% | 0.01% | -11.1% |
| Q2 2020 | $124,459,000 | -27.1% | 2,567,744 | -36.5% | 0.01% | -40.0% |
| Q1 2020 | $170,787,000 | -0.3% | 4,042,296 | +1.0% | 0.02% | +25.0% |
| Q4 2019 | $171,277,000 | +37.7% | 4,003,677 | +15.9% | 0.01% | +33.3% |
| Q3 2019 | $124,360,000 | +0.2% | 3,455,400 | -25.6% | 0.01% | 0.0% |
| Q2 2019 | $124,157,000 | -5.0% | 4,644,863 | -4.5% | 0.01% | -10.0% |
| Q1 2019 | $130,644,000 | +67.0% | 4,865,697 | +0.5% | 0.01% | +42.9% |
| Q4 2018 | $78,250,000 | -44.9% | 4,839,186 | -29.2% | 0.01% | -36.4% |
| Q3 2018 | $141,959,000 | +59.5% | 6,838,199 | +17.4% | 0.01% | +57.1% |
| Q2 2018 | $88,978,000 | -5.2% | 5,826,875 | +39.5% | 0.01% | -12.5% |
| Q1 2018 | $93,826,000 | -6.2% | 4,175,749 | +25.7% | 0.01% | 0.0% |
| Q4 2017 | $100,047,000 | -18.0% | 3,322,938 | +2.5% | 0.01% | -27.3% |
| Q3 2017 | $122,067,000 | +16.8% | 3,240,379 | -13.6% | 0.01% | +22.2% |
| Q2 2017 | $104,551,000 | -6.1% | 3,748,468 | +15.8% | 0.01% | -10.0% |
| Q1 2017 | $111,319,000 | +15.1% | 3,237,798 | -3.5% | 0.01% | +11.1% |
| Q4 2016 | $96,728,000 | -2.2% | 3,354,026 | +7.9% | 0.01% | -10.0% |
| Q3 2016 | $98,857,000 | +33.8% | 3,107,828 | +36.6% | 0.01% | +25.0% |
| Q2 2016 | $73,858,000 | -21.5% | 2,275,325 | -32.4% | 0.01% | -20.0% |
| Q1 2016 | $94,072,000 | +11.5% | 3,364,426 | +42.1% | 0.01% | +11.1% |
| Q4 2015 | $84,391,000 | +34.2% | 2,367,221 | +22.7% | 0.01% | +50.0% |
| Q1 2015 | $62,887,000 | +10.7% | 1,929,610 | +7.8% | 0.01% | 0.0% |
| Q4 2014 | $56,824,000 | +21.6% | 1,789,626 | -5.2% | 0.01% | +20.0% |
| Q3 2014 | $46,716,000 | +3.9% | 1,887,017 | -5.2% | 0.01% | 0.0% |
| Q2 2014 | $44,965,000 | -8.7% | 1,990,425 | -1.7% | 0.01% | -16.7% |
| Q1 2014 | $49,252,000 | +1.7% | 2,024,331 | +3.3% | 0.01% | +100.0% |
| Q4 2013 | $48,440,000 | -16.4% | 1,959,275 | -7.1% | 0.00% | -57.1% |
| Q3 2013 | $57,930,000 | +62.2% | 2,108,880 | +7.2% | 0.01% | +40.0% |
| Q2 2013 | $35,717,000 | – | 1,967,942 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |